As Gilead Seeks New CEO, Second Quarter Shows Stability
Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.
Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.